2025 annual financial data
Alnylam Pharmaceuticals 2025 Operating cash flow growth
Direct answer
Operating cash flow growth was 6,405.1%.
Operating income was 501,578,000 USD and net income was 313,747,000 USD.
Operating cash flow was 524,080,000 USD.
Get free Alnylam Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 3,713,937,000 USD
- Operating income
- 501,578,000 USD
- Net income
- 313,747,000 USD
- Operating cash flow
- 524,080,000 USD